Literature DB >> 23452163

Gut microbiota and non-alcoholic fatty liver disease: new insights.

J Aron-Wisnewsky1, B Gaborit, A Dutour, K Clement.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a severe liver disease that is increasing in prevalence with the worldwide epidemic of obesity and its related insulin-resistance state. A 'two-hit' mechanism has been proposed; however, the complete physiopathogenesis remains incompletely understood. Evidence for the role of the gut microbiota in energy storage and the subsequent development of obesity and some of its related diseases is now well established. More recently, a new role of gut microbiota has emerged in NAFLD. The gut microbiota is involved in gut permeability, low-grade inflammation and immune balance, it modulates dietary choline metabolism, regulates bile acid metabolism and produces endogenous ethanol. All of these factors are molecular mechanisms by which the microbiota can induce NAFLD or its progression toward overt non-alcoholic steatohepatitis.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23452163     DOI: 10.1111/1469-0691.12140

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  81 in total

Review 1.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

2.  Yes-Associated Protein in Kupffer Cells Enhances the Production of Proinflammatory Cytokines and Promotes the Development of Nonalcoholic Steatohepatitis.

Authors:  Kyoungsub Song; Hyunjoo Kwon; Chang Han; Weina Chen; Jinqiang Zhang; Wenbo Ma; Srikanta Dash; Chandrashekhar R Gandhi; Tong Wu
Journal:  Hepatology       Date:  2020-04-11       Impact factor: 17.425

Review 3.  Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective.

Authors:  Jun-Ling Han; Hui-Ling Lin
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 4.  Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Sanja Stojsavljević; Marija Gomerčić Palčić; Lucija Virović Jukić; Lea Smirčić Duvnjak; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 5.  Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.

Authors:  Helen L Reeves; Marco Y W Zaki; Christopher P Day
Journal:  Dig Dis Sci       Date:  2016-02-26       Impact factor: 3.199

Review 6.  The effects of gastrointestinal surgery on gut microbiota: potential contribution to improved insulin sensitivity.

Authors:  Judith Aron-Wisnewsky; Karine Clement
Journal:  Curr Atheroscler Rep       Date:  2014-11       Impact factor: 5.113

Review 7.  Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?

Authors:  Giovanni Cammarota; Gianluca Ianiro; Stefano Bibbò; Antonio Gasbarrini
Journal:  Intern Emerg Med       Date:  2014-03-25       Impact factor: 3.397

Review 8.  Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Authors:  Kareem Hassan; Varun Bhalla; Mohammed Ezz El Regal; H Hesham A-Kader
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 9.  The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases.

Authors:  J Mark Brown; Stanley L Hazen
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

Review 10.  Bile acids as metabolic regulators.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Curr Opin Gastroenterol       Date:  2015-03       Impact factor: 3.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.